the hard part is understanding the “junk” in the Lovenox mixture and ensuring that it is within the lot-to-lot variation of branded Lovenox.
With respect to understanding the "junk".... Could Teva obtain approval without understanding the "junk" to the same degree as MNTA? Basically - is MNTA's understanding of the "junk" the bar or the potential ceiling for the FDA?